Directorie lands No. 2284 on Inc. 5000 for third straight year

Directorie ranked No. 2284 on the 2026 Inc. 5000 after posting 147.8% revenue growth over three years, extending its streak on the annual list to a third consecutive year. The recognition puts the Chesterfield, Missouri-based commercialization partner among America’s fastest-growing private companies as it pushes deeper into pharma and biotech work.

Why it matters: - Directorie’s third straight appearance on the Inc. 5000 signals sustained growth in a crowded market for pharmaceutical and biotech services. - The ranking highlights independent companies that are expanding revenue, adding jobs and shaping parts of the U.S. economy. - Directorie said the growth supports work that has touched more than 100 million patients through therapies the company helped bring to market.

What happened: - Directorie announced it ranked No. 2284 on the 2026 Inc. 5000 list. - The Chesterfield, Missouri-based company posted 147.8% three-year revenue growth. - The 2026 list covers the fastest-growing private companies in America. - Directorie made the list for the third consecutive year.

The details: - Inc. ranked companies by percentage revenue growth from 2022 to 2025. - To qualify, a company had to be founded and generating revenue by March 31, 2022. - Companies had to be U.S.-based, privately held, for-profit and independent as of Dec. 31, 2025. - The 2022 revenue minimum was $100,000. - The 2025 revenue minimum was $2 million. - The median three-year revenue growth rate among the 5,000 honorees was 130%. - The listed companies added more than 627,208 jobs over the past three years. - Inc. will celebrate honorees at its 2026 Inc. 5000 Conference & Gala on Oct. 14-16 in Dallas, Texas. - The top 500 companies will appear in the Fall issue of Inc. Magazine. - A full list and searchable database are available in Inc.'s Inc. 5000 coverage.

Between the lines: - Directorie is positioning growth as proof of execution in a specialized healthcare niche, not just a revenue milestone. - The company’s emphasis on patient impact suggests a broader commercial story tied to drug launches and therapy adoption. - Inc.’s methodology favors companies that show sustained, not one-time, expansion.

What's next: - Directorie is likely to use the ranking as external validation as it competes for pharmaceutical and biotech clients. - Inc. honorees will get further visibility at the Dallas conference and in the magazine’s Fall issue. - Directorie says it is “just getting started,” signaling continued growth ambitions.

The bottom line: - Directorie’s No. 2284 ranking extends a three-year run on the Inc. 5000 and underscores durable growth in a high-stakes healthcare services market.